BioWorld

Feb. 11, 2002

Cephalon, Industry Thrown 'Off Balance' By Enron Storm

If there's one thing for sure in biotechnology, it's uncertainty. And volatility, occasionally tilting into chaos. And hysteria, practically at the drop of a hat. (BioWorld Financial Watch) Read More

Public Financing Of Biotechnology: January 2002

Other Financings Of Public Biotechnology Companies: January 2002

Venture Capital And Corporate Investments In Biotechnology Companies: January 2002

Money Raised Year To Date

Stock Winners and Losers For The Week

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 31, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...